ZP-9830 is under clinical development by Zealand Pharma and currently in Phase I for Chronic Inflammation. According to GlobalData, Phase I drugs for Chronic Inflammation does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ZP-9830 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZP-9830 overview
ZP-9830 is under development for the treatment of T cell driven chronic inflammatory diseases. The drug candidate acts by targeting potassium voltage gated channel subfamily A member 3 (Kv1.3). It is administered through intravenous and subcutaneous route.
It was also under development for the treatment of inflammatory bowel disease.
Zealand Pharma overview
Zealand Pharma (Zealand) is a biotechnology company that discovers and develops peptide-based medicines. The company’s pipeline products include liraglutide, a long-acting GLP-2 analog in development for the treatment of short bowel syndrome; dasiglucagon for congenital hyperinsulinism and bi-hormonal artificial pancreas systems; survodutide (BI 456906) treats obesity and nonalcoholic steatohepatitis; ZP8396 for overweight and obesity; dapiglutide for obesity. Zealand conducts research and development and in-licensing programs. It has operations in Denmark and the US. Zealand is headquartered in Soeborg, Denmark.
For a complete picture of ZP-9830’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
